BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 36658489)

  • 1. The cost of illness analysis of inflammatory bowel disease.
    Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
    BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of inflammatory bowel disease in Germany.
    Stark R; König HH; Leidl R
    Pharmacoeconomics; 2006; 24(8):797-814. PubMed ID: 16898849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
    Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
    Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
    Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
    Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
    Busingye D; Pollack A; Chidwick K
    PLoS One; 2021; 16(5):e0252458. PubMed ID: 34043730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)].
    Veselov AV; Belousova EA; Bakulin IG; Uspenskiy YP; Dreval RO; Shkurko TV; Kashnikov BN; Fominykh YA; Knyazev OV; Romanov RI; Skalinskaia MI; Shipitsyn VV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Oct; 28(Special Issue):1137-1145. PubMed ID: 33219771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996.
    Torres EA; De Jesús R; Pérez CM; Iñesta M; Torres D; Morell C; Just E
    P R Health Sci J; 2003 Sep; 22(3):253-8. PubMed ID: 14619451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.
    Severs M; Mangen MJ; van der Valk ME; Fidder HH; Dijkstra G; van der Have M; van Bodegraven AA; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; Ponsioen CY; Vermeijden JR; van der Meulen-de Jong AE; Pierik M; Siersema PD; Oldenburg B;
    J Crohns Colitis; 2017 Mar; 11(3):342-352. PubMed ID: 27647859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    van Linschoten RCA; Visser E; Niehot CD; van der Woude CJ; Hazelzet JA; van Noord D; West RL
    Aliment Pharmacol Ther; 2021 Aug; 54(3):234-248. PubMed ID: 34114667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Lee J; Im JP; Han K; Kim J; Lee HJ; Chun J; Kim JS
    Gut Liver; 2020 Jan; 14(1):89-99. PubMed ID: 31158951
    [No Abstract]   [Full Text] [Related]  

  • 15. Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
    Vadstrup K; Alulis S; Borsi A; Elkjaer Stallknecht S; Nielsen A; Rikke Jørgensen T; Wennerström C; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Jan; 55(1):41-46. PubMed ID: 31960726
    [No Abstract]   [Full Text] [Related]  

  • 16. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
    Rankala R; Mattila K; Voutilainen M; Mustonen A
    Scand J Gastroenterol; 2021 Jun; 56(6):687-692. PubMed ID: 33826877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
    Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
    J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
    Schoepfer A; Vavricka SR; Brüngger B; Blozik E; Bähler C
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):350-357. PubMed ID: 31834046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Ng SC; Shi HY; Hamidi N; Underwood FE; Tang W; Benchimol EI; Panaccione R; Ghosh S; Wu JCY; Chan FKL; Sung JJY; Kaplan GG
    Lancet; 2017 Dec; 390(10114):2769-2778. PubMed ID: 29050646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.